Honest stock price momentum in the healthcare sector is boosted by FDA approvals and M&A activity. Analysts highlight improving EBIT margins and free cash flow ratios as key drivers into mid-year performance. A significant factor in that performance is likely its valuation. Its current price-to-earnings (P/E) ratio is 52, down from a peak of 63 in February. Still, that is far above the S&P 500 average of 31 and well above that of its major competitors. For privacy and data protection related complaints please contact us at [email protected] . Please read our PRIVACY POLICY STATEMENT for more information on handling of personal data. Honest stock price outlook favors growth sectors, with AI chipmakers showing forward P/E ratios justified by improving gross margins. Equity research notes solid backlog orders that could sustain double-digit revenue expansion through FY
